[Spironolactone in digitalis-requiring cardiac insufficiency following pacemaker implantation].
In a retrospective study conducted in 213 patients with cardiac pacemakers having severe bradycardiac heart failure with oedema, the addition of the aldosterone-antagonist spironolactone to a diuretic therapy was shown to have a favourable influence on the degree of compensation. This has been confirmed in 26 patients under the conditions of a drug interruption period, and in 24 other patients, who were treated with spironolactone after being decompensated under the therapy with digitalis and diuretic or without diuretic. The application of triamterene with a thiazide did not show this positive effect.
D000368:Aged; D004070:Digitalis; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial; D010946:Plants, Medicinal; D010947:Plants, Toxic; D012189:Retrospective Studies; D013148:Spironolactone / Q000627:therapeutic use*
D004232:Diuretics; D013148:Spironolactone
Spironolacton bei digitalis-bedürftiger Herzinsuffizienz nach Schrittmacher-Implantation.